|
 Prostate cancer cells need testosterone to grow and spread.
Researchers focused on a common treatment known as androgen
deprivation therapy (ADT), which works by depriving tumor cells of
testosterone. Side effects can include sexual dysfunction, weight
gain and fatigue.
Patients with prostate cancer who received hormone therapy were 23
percent more likely to develop depression and 29 percent more likely
to have inpatient psychiatric treatment than men who received
alternative treatments, the study found.
“The take-home message is that the list of potential side effects of
hormone therapy is continuing to grow,” said senior study author Dr.
Paul Nguyen of Brigham and Women’s Hospital and Harvard Medical
School in Boston.
“Any man with prostate cancer considering hormone therapy should
find out from their doctor exactly how big the benefit is expected
to be in their specific situation so they can weigh it against the
list of possible side effects,” Nguyen added by email.
To explore the link between hormone therapy and depression, Nguyen
and colleagues examined data on more than 78,000 men age 66 and
older who were treated for prostate cancer from 1992 to 2006.
They followed men for three years, and excluded patients with
psychiatric diagnoses in the year before they were diagnosed with
tumors.
Almost 45,000 men in the study received hormone therapy, and they
tended to have more advanced disease. They were about 76 years old
on average, about two years older than the typical age of the men
who received different treatments.
From six months to three years after diagnosis, 7.1 percent of the
men on hormone therapy had new cases of depression, compared with
5.2 percent of the others in the study.
During this period, 2.8 percent of men on hormone therapy had
inpatient psychiatric treatment, compared with 1.9 percent of their
peers. In addition, 3.4 percent received outpatient psychiatric
services, versus 2.5 percent of the other men.
[to top of second column] |
One limitation of the study is that researchers didn’t have data on
drug treatments for depression, the authors note in the Journal of
Clinical Oncology. It’s also possible that the older age or more
advanced tumors of the men receiving hormone therapy might have
influenced their odds of depression.
Side effects of hormone therapy such as fatigue, lower libido and
sexual performance, and decreased muscle mass may also play a role,
said Dr. Sumanta Pal of the City of Hope Comprehensive Cancer Center
in Duarte, California.
“Although it’s within reason to construe that hormone therapy may
have a direct impact on the centers in the brain that control mood,
it’s important to acknowledge that the side effects of hormone
therapy may also contribute to the development of depression,” Pal,
who wasn’t involved in the study, said by email.
Because the risk of depression rose with longer treatment, men who
consider hormone therapy may want consider the duration of therapy
when deciding whether the benefits are worth the potential side
effects, Pal added.
“Prostate cancers that carry a higher risk can either be managed
with surgery alone or a combination of radiation with hormone
therapy,” Pal said. “In the latter scenario, patients with high-risk
localized prostate cancer may get up to three years of hormone
therapy, apparently putting them at substantial risk for
depression.”
SOURCE: http://bit.ly/1WqaypW Journal of Clinical Oncology, online
April 11, 2016.
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
